Hengrui and Kailera report positive phase 3 results for dual GLP-1/GIP agonist in obesity treatment EP News Bureau Jul 17, 2025 HRS9531 achieves significant weight reduction in Phase 3 trial, with plans for NDA submission in China and global development as…
